Brand Name :
Addyi
Synonyms :
flibanserin
Class :
Serotonin 5-HT Receptor Agonists
Dosage Forms & Strengths
Tablet
100mg
100mg orally once at bedtime
If there is no progress after eight weeks, treatment is stopped
Not indicated
Refer adult dosing
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may enhance the serum concentrations of flibanserin
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may enhance the serum concentrations of P-glycoprotein-ABCB1 inhibitors
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
May increase the hypoglycemic effect of each other when combined
ciprofloxacin increases the level of flibanserin by affecting the CYP3A4 metabolism of hepatic/intestinal enzymes. Coadministration with strong CYP3A4 inhibitors is contraindicated. Severe hypotension or syncope may occur .
when both drugs are combined, there may be an increased effect of cobimetinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
lapatinib increases the effect of flibanserin by altering the intestinal or hepatic CYP3A4 enzyme metabolism
When both drugs are combined, there may be an increased effect of flibanserin by affecting hepatic or intestinal enzyme CYP3A4 metabolism
when both drugs are combined, there may be an increase in the effect of flibanserin by affecting hepatic or intestinal enzyme cyp3a4 metabolism
may have an increasingly adverse effect when combined with selective serotonin reuptake inhibitors
may enhance the serum concentrations of flibanserin
may enhance the serum concentrations of flibanserin
may enhance the serum concentrations of flibanserin
may enhance the serum concentrations of flibanserin
may enhance the serum concentrations of flibanserin
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may enhance the serum concentrations of P-glycoprotein-ABCB1 inhibitors
may enhance the serum concentrations of P-glycoprotein-ABCB1 inhibitors
may enhance the serum concentrations of P-glycoprotein-ABCB1 inhibitors
may increase the CNS depressant effect of flibanserin
may increase the CNS depressant effect of flibanserin
may increase the CNS depressant effect of flibanserin
may increase the CNS depressant effect of flibanserin
may increase the CNS depressant effect of flibanserin
flibanserin: they may diminish the serum concentration of CYP3A4 Inducers
flibanserin: they may diminish the serum concentration of CYP3A4 Inducers
flibanserin: they may diminish the serum concentration of CYP3A4 Inducers
flibanserin: they may diminish the serum concentration of CYP3A4 Inducers